Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Ophthalmology
Description:
Welcome to our podcast. Today, we’re exploring glaucoma, often called the 'silent thief of sight.' Glaucoma is a group of eye conditions that damage the optic nerve, usually due to high pressure inside the eye. What makes glaucoma so dangerous is that it usually develops slowly, without early symptoms. By the time vision loss is noticed, the damage is often permanent. The best defence is regular eye exams, especially if you’re over 40 or have a family history of eye disease. Early detection and treatment can protect your vision and maintain your quality of life. Remember, taking care of your eyes today can help prevent vision loss tomorrow.
See More Webinars @ Hidoc Webinars
1.
Advances in "next generation" photoactive cancer therapy
2.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
3.
The American College of Physicians updated its recommendations for colorectal cancer screening.
4.
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
5.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
1.
Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions
2.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
3.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
4.
Modern Developments in Oncology for Specialists
5.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part XII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge